Drug Profile
Research programme: oral film benign prostatic hyperplasia therapeutics - IntelGenx
Alternative Names: INT0025; INT0025/2010; INT0026; INT0026/2011Latest Information Update: 22 Apr 2019
Price :
$50
*
At a glance
- Originator IntelGenx Corp.
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Benign prostatic hyperplasia